These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27927042)

  • 61. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence.
    Kalechstein AD; Newton TF; Green M
    J Neuropsychiatry Clin Neurosci; 2003; 15(2):215-20. PubMed ID: 12724464
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence.
    Sliman S; Waalen J; Shaw D
    Cardiovasc Toxicol; 2016 Oct; 16(4):381-9. PubMed ID: 26661075
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
    National Toxicology Program
    NTP CERHR MON; 2005 Jul; (16):vii-III1. PubMed ID: 16130031
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Opioids and methamphetamine: a tale of two crises.
    The Lancet
    Lancet; 2018 Feb; 391(10122):713. PubMed ID: 29486928
    [No Abstract]   [Full Text] [Related]  

  • 66. Methamphetamine use in Dayton, Ohio: preliminary findings from the Ohio Substance Abuse Monitoring Network.
    Daniulaityte R; Carlson RG; Kenne DR
    J Psychoactive Drugs; 2007 Sep; 39(3):211-21. PubMed ID: 18159774
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review.
    Nordahl TE; Salo R; Leamon M
    J Neuropsychiatry Clin Neurosci; 2003; 15(3):317-25. PubMed ID: 12928507
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methamphetamine abuse and "meth mouth".
    Rhodus NL; Little JW
    Northwest Dent; 2005; 84(5):29, 31, 33-7. PubMed ID: 16317979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
    Sulaiman AH; Said MA; Habil MH; Rashid R; Siddiq A; Guan NC; Midin M; Nik Jaafar NR; Sidi H; Das S
    Compr Psychiatry; 2014 Jan; 55 Suppl 1():S89-94. PubMed ID: 23433219
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The rise of methamphetamine in Southeast and East Asia.
    McKetin R; Kozel N; Douglas J; Ali R; Vicknasingam B; Lund J; Li JH
    Drug Alcohol Rev; 2008 May; 27(3):220-8. PubMed ID: 18368602
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cognitive impairment in individuals currently using methamphetamine.
    Simon SL; Domier C; Carnell J; Brethen P; Rawson R; Ling W
    Am J Addict; 2000; 9(3):222-31. PubMed ID: 11000918
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A potential role for N-acetylcysteine in the management of methamphetamine dependence.
    McKetin R; Dean OM; Baker AL; Carter G; Turner A; Kelly PJ; Berk M
    Drug Alcohol Rev; 2017 Mar; 36(2):153-159. PubMed ID: 27241765
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Frequency of osteoporosis in 46 men with methamphetamine abuse hospitalized in a National Hospital.
    Kim EY; Kwon DH; Lee BD; Kim YT; Ahn YB; Yoon KY; Sa SJ; Cho W; Cho SN
    Forensic Sci Int; 2009 Jul; 188(1-3):75-80. PubMed ID: 19398174
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An investigation of relations between crystal methamphetamine use and posttraumatic stress disorder.
    Smith RC; Blumenthal H; Badour C; Feldner MT
    Addict Behav; 2010 Jun; 35(6):625-7. PubMed ID: 20153121
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methamphetamine and the expanding complications of amphetamines.
    Albertson TE; Derlet RW; Van Hoozen BE
    West J Med; 1999 Apr; 170(4):214-9. PubMed ID: 10344175
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats.
    Carson DS; Cornish JL; Guastella AJ; Hunt GE; McGregor IS
    Neuropharmacology; 2010 Jan; 58(1):38-43. PubMed ID: 19560473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. METHAMPHETAMINE: WHERE WILL THE STAMPEDE TAKE US?
    Sullivan D; McDonough Michael
    J Law Med; 2015 Sep; 23(1):41-9. PubMed ID: 26554196
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Effect of Buprenorphine on Methamphetamine Cravings.
    Salehi M; Emadossadat A; Kheirabadi GR; Maracy MR; Sharbafchi MR
    J Clin Psychopharmacol; 2015 Dec; 35(6):724-7. PubMed ID: 26468683
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Epidemiology and public health Consequences of methamphetamine use in California's Central Valley.
    Gibson DR; Leamon MH; Flynn N
    J Psychoactive Drugs; 2002; 34(3):313-9. PubMed ID: 12422943
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings.
    Härtel-Petri R; Krampe-Scheidler A; Braunwarth WD; Havemann-Reinecke U; Jeschke P; Looser W; Mühlig S; Schäfer I; Scherbaum N; Bothe L; Schaefer C; Hamdorf W
    Pharmacopsychiatry; 2017 May; 50(3):96-104. PubMed ID: 28445899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.